Nibrozetone is under clinical development by EpicentRx and currently in Phase I for Central Nervous System (CNS) Tumor. According to GlobalData, Phase I drugs for Central Nervous System (CNS) Tumor have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nibrozetone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nibrozetone overview

Nibrozetone (RRX-001) is under development for the treatment of advanced solid tumors, metastatic colorectal cancer, small-cell lung cancer, endometrial lesions and associated pain, Parkinson's disease, amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND), other neurodegenerative diseases, radiation induced oral mucositis, acute radiation syndrome and recurrent or progressive malignant pediatric solid and central nervous system tumors. It is administered through intravenous, subcutaneous and as a hepatic artery infusion. The drug candidate is a dinitroazetidine radiosensitizer which acts by targeting NLRP3 and KEAP1. It is is being developed based on CyNRGY platform.

The drug candidate was also under development for advanced cholangiocarcinoma, refractory and relapsed multiple myeloma, cerebral (fatal) malaria, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, lymphoma, brain metastases, relapsed and refractory multiple myeloma, non-small cell lung cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, high grade neuroendocrine tumors, lymphoma, cerebral malaria, newly diagnosed high-grade glioma, including anaplastic glioma, glioblastoma, metastatic castration resistant neuroendocrine prostate cancer (NEPC), gliosarcoma, liver cancer and inflammation.

EpicentRx overview

EpicentRx is a biopharmaceutical company that carries out the development of novel therapies aimed at targeting cancer and chronic diseases. The company’s main products include the PRETECT Platform, featuring the Phase 3 investigational product RRx-001, and the AdAPT Platform, with its lead clinical stage candidate AdAPT-001. EpicentRx has developed the proprietary eLoop device, designed for optimized delivery of intravenous treatments. The company’s products are intended for use in the pharmaceutical industry, specifically for the treatment of various forms of cancer and chronic inflammatory diseases. The company operates in the US and China. EpicentRx is headquartered in La Jolla, California, the US.

For a complete picture of Nibrozetone’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.